The takeaway
Inhibrx Biosciences, Inc. shows a pronounced seasonal pattern over 2 years of data — strongest in October (+72.0%) and softest in April (−12.2%).
Right now
In July, the stock has risen 100% of years, averaging +27.5%, about +25.4 pts better than the S&P 500.
The full picture
Inhibrx Biosciences, Inc.'s most dependable month has been October, higher in 2 of 2 years; April has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in October (+71.0 pts); it has trailed the market most in April (−13.9 pts).
“vs S&P” is Inhibrx Biosciences, Inc.’s average for a month minus the S&P 500’s average for that same month — isolating Inhibrx Biosciences, Inc.’s own seasonal edge from broad market drift.
Reality check
Not enough recent October history to say whether the pattern still holds.
Figures are the typical (median) October return and how often it rose — the last 2 years versus the last 2(the heatmap’s default window). This verdict stays anchored to that 2-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Dependability is the through-line here. October stands out, higher in all 2 Octobers, but it heads a clutch of months that pull the year reliably upward.
Its average (+72.0%) and median (+72.0%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even October ranges by 68.3% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: October has cleared the S&P 500 by +71.0 points above the index. That consistency sets it apart from the field, where the average stock manages October only about 53% of the time.
A few other months pull their weight: February, March, and May have also closed higher more often than not. On the other side of the ledger, April has been the soft spot — the weakest of 3 months that average a loss (−12.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in April, January, and June. Its roughest month on record was a −21.4% June in 2024 — a reminder of how hard even a seasonal name can fall.
The takeaway is less about when to buy than what to expect: October aside, the stock's months offer little reliable tilt. With a short 2-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (October), its worst (April), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2024 its best month (October, +72.0%) has run well ahead of its worst (April, −12.2%) — the heatmap above shows how steady that gap has been year to year.
October has been the strongest, averaging +72.0% and closing higher in all 2 years on record since 2024.
It's the weakest, averaging −12.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade